A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
A Phase 2/3, Multicenter, Randomized Open-Label Study of Zanzalintinib vs Everolimus in Participants With Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
druginfo@exelixis.com1-888-EXELIXIS (888-393-5494)
650-837-7400
Albuquerque, New Mexico 87131, United States
Chapel Hill, North Carolina 27599, United States
Pittsburgh, Pennsylvania 15232, United States
Milwaukee, Wisconsin 53226, United States
Lille, 59037, France
Bologna, 40138, Italy
Orbassano to, 10043, Italy
Amsterdam, 1066 CX, Netherlands
Gliwice, 44-102, Poland
Krakow, 30-688, Poland
Warsaw, 02-034, Poland
Santiago de Compostela, 15706, Spain